Form 4: United Therapeutics Director Sells 255 Shares at $355.76
SEC Form 4
A director at United Therapeutics Corp sold 255 shares of common stock at a price of $355.7651 per share on December 30, 2024.
Summary
- Nilda Mesa, a director at United Therapeutics Corporation, sold 255 shares of the company's common stock on December 30, 2024.
- The sale price was $355.7651 per share.
- Following the transaction, Ms. Mesa directly owns 5,528 shares of United Therapeutics stock.
Sentiment
Score: 5
Explanation: The document is a neutral report of a stock sale by a director, with no inherent positive or negative sentiment.
Industry Context
This is a routine Form 4 filing, which is common when company insiders trade shares. It provides transparency into the trading activities of company directors.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, and this transaction is consistent with typical insider trading activity.
- The sale by a director is not unusual and is a common occurrence in the market.
Stakeholder Impact
- The sale of shares by a director may have a minor impact on shareholder sentiment, but is unlikely to have a significant effect on the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 12/30/2024 | Date of the stock sale transaction. |
| 12/31/2024 | Date of signature for the SEC filing. |
Keywords
United Therapeutics, UTHR, stock sale, insider trading, director, Nilda Mesa, share transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.